Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

Exclusion Criteria

• •Active systemic infection requiring anti-infective therapy within 28 days prior to first dose of IMP
• •Active cardiovascular disease
• •Having a second active primary malignancy, requiring systemic administration of any cancer-related therapy
• •Liver dysfunction
• •Untreated brain metastasis and/or unstable neurological dysfunction
• •Inflammatory bowel disease
• •Active and untreated hyperthyroidism
• •Lupus erythematosus within past 5 years